{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:02:14Z","timestamp":1775055734147,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":448,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1002\/jcph.315","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T04:32:43Z","timestamp":1398659563000},"page":"1134-1143","source":"Crossref","is-referenced-by-count":18,"title":["Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes"],"prefix":"10.1002","volume":"54","author":[{"given":"Oneeb","family":"Majid","sequence":"first","affiliation":[{"name":"Eisai Ltd.; Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anubha","family":"Gupta","sequence":"additional","affiliation":[{"name":"Eisai Ltd.; Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Reyderman","sequence":"additional","affiliation":[{"name":"Eisai Inc.; Woodcliff Lake NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Olivo","sequence":"additional","affiliation":[{"name":"Eisai Inc.; Woodcliff Lake NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Hussein","sequence":"additional","affiliation":[{"name":"Eisai Ltd.; Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,10]]},"reference":[{"issue":"7","key":"10.1002\/jcph.315-BIB0001|jcph315-cit-0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1002\/jcph.315-BIB0002|jcph315-cit-0002","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"10.1002\/jcph.315-BIB0003|jcph315-cit-0003","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","article-title":"Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase","volume":"7","author":"Okouneva","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1002\/jcph.315-BIB0004|jcph315-cit-0004","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"issue":"3","key":"10.1002\/jcph.315-BIB0005|jcph315-cit-0005","first-page":"1013","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"key":"10.1002\/jcph.315-BIB0006|jcph315-cit-0006","unstructured":"http:\/\/www.halaven.com\/"},{"key":"10.1002\/jcph.315-BIB0007|jcph315-cit-0007","first-page":"275","article-title":"Antiproliferative effects ofhalichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro","volume":"48","author":"Kuznetsov","year":"2007","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"9769","key":"10.1002\/jcph.315-BIB0008|jcph315-cit-0008","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/jcph.315-BIB0009|jcph315-cit-0009","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3816\/CBC.2010.n.023","article-title":"Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer","volume":"10","author":"Twelves","year":"2010","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1002\/jcph.315-BIB0010|jcph315-cit-0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10637-012-9829-3","article-title":"Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole","volume":"31","author":"Devriese","year":"2013","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1002\/jcph.315-BIB0011|jcph315-cit-0011","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-012-1976-x","article-title":"Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment","volume":"70","author":"Devriese","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1002\/jcph.315-BIB0012|jcph315-cit-0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/dmd.111.042762","article-title":"Mass balance study of [(1)(4)C]eribulin in patients with advanced solid tumors","volume":"40","author":"Dubbelman","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1002\/jcph.315-BIB0013|jcph315-cit-0013","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1158\/1078-0432.CCR-08-2429","article-title":"A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies","volume":"15","author":"Goel","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1002\/jcph.315-BIB0014|jcph315-cit-0014","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s10637-012-9893-8","article-title":"A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors","volume":"31","author":"Lesimple","year":"2013","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1002\/jcph.315-BIB0015|jcph315-cit-0015","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s10637-011-9741-2","article-title":"Eribulin mesylate in patients with refractory cancers: a Phase I study","volume":"30","author":"Mukohara","year":"2012","journal-title":"Invest New Drugs"},{"issue":"12","key":"10.1002\/jcph.315-BIB0016|jcph315-cit-0016","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1158\/1078-0432.CCR-09-0360","article-title":"Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1002\/jcph.315-BIB0017|jcph315-cit-0017","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24 Suppl 3","key":"10.1002\/jcph.315-BIB0018|jcph315-cit-0018","article-title":"Open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes","volume":"72","author":"Kaufman","year":"2012","journal-title":"Cancer Res"},{"issue":"6","key":"10.1002\/jcph.315-BIB0019|jcph315-cit-0019","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00280-010-1456-0","article-title":"Population pharmacokinetic\/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients","volume":"66","author":"Lu","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1002\/jcph.315-BIB0020|jcph315-cit-0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/clpt.2009.64","article-title":"Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development","volume":"86","author":"Wang","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1002\/jcph.315-BIB0021|jcph315-cit-0021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.315","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.315\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:03:39Z","timestamp":1657803819000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.315"}},"subtitle":["The Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2014,6,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.315","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6,10]]}}}